EN
Instrument Fundamentals
| Date | Close | Change | Change (%) | Open | High | Low |
|---|
News
Advances in vaccine technology and the road ahead
The 7.2% return this week takes BioNTech's (NASDAQ:BNTX) shareholders five-year gains to 271%
C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors Makes New Investment in BioNTech SE (NASDAQ:BNTX)
RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer
Morgan Stanley Remains a Buy on BioNTech SE (BNTX) | Markets Insider
mRNA Therapeutics Contract Development & Manufacturing Organization Market: Industry Insights and Future Projections
BioNTech SE (NASDAQ:BNTX) Shares Sold by Baillie Gifford & Co.
Vontobel Holding Ltd. Has $2.44 Million Position in BioNTech SE (NASDAQ:BNTX)
Banque Pictet & Cie SA Lowers Stake in BioNTech SE (NASDAQ:BNTX)
Banque Pictet & Cie SA Decreases Stock Holdings in BioNTech SE (NASDAQ:BNTX)
Van ECK Associates Corp Boosts Stock Position in BioNTech SE (NASDAQ:BNTX)
Morgan Stanley Reaffirms Their Buy Rating on BioNTech SE (BNTX)
BioNTech SE (NASDAQ:BNTX) Given Consensus Rating of "Moderate Buy" by Brokerages
BioNTech SE (NASDAQ:BNTX) Shares Purchased by abrdn plc
Bank of America Securities Reaffirms Their Buy Rating on BioNTech SE (BNTX)
BioNTech SE (NASDAQ:BNTX) Sees Large Increase in Short Interest
BioNTech Completes Acquisition of Biotheus | The Manila Times
Alphabet and Amazon Report: Global Week Ahead - February 3, 2025 - Zacks.com
Sivik Global Healthcare LLC Acquires Shares of 15,000 BioNTech SE (NASDAQ:BNTX)
Union Bancaire Privee UBP SA Makes New Investment in BioNTech SE (NASDAQ:BNTX)
Slow Capital Inc. Decreases Holdings in BioNTech SE (NASDAQ:BNTX)
SG Americas Securities LLC Buys 33,375 Shares of BioNTech SE (NASDAQ:BNTX)
Brokerages Set BioNTech SE (NASDAQ:BNTX) Target Price at $142.72
